Unichem Laboratories Ltd (UNICHEMLAB) — shareholding pattern, promoter holding, financials and share price
About Unichem Laboratories Ltd (UNICHEMLAB)
Unichem Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as UNICHEMLAB and on the BSE under scrip code 506690. Its ISIN is INE351A01035.
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. [1]
Unichem Laboratories Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients and operates through four divisions. It has five manufacturing facilities across India, enjoying numerous global certifications.
The company has a rich history of collaborations and initiatives, having set up various R&D centers and strategic plants since its inception in 1962, illustrating its commitment to growth and innovation.
Listed peers in Pharmaceuticals: Orchid Pharma Ltd, IOL Chemicals & Pharmaceuticals Ltd, Zota Health Care Ltd, RPG Life Sciences Ltd, Gujarat Themis Biosyn Ltd, Gufic BioSciences Ltd.
Valuation & Returns
10 Jul 2026At ₹639.5 a share on 10 Jul 2026, Unichem Laboratories Ltd (UNICHEMLAB) was valued at a price-to-earnings ratio of 17.81x against an industry P/E of 36.41x and a price-to-book of 1.66x on a book value of ₹385.97 per share as of Mar 2026. Solomo computes return on equity of 9.3% and return on capital employed of 10.07% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.81x
- Industry P/E
- 36.41x
- P/B
- 1.66x
- EPS (TTM)
- ₹35.91
- Book value / share
- ₹385.97
- ROE
- 9.3%
- ROCE
- 10.07%
- ROA
- 6.77%
- Debt / equity
- 0.18x
- Dividend yield
- 0%
- EBITDA margin
- 20.4%
- 52-week range
- ₹280 – ₹685.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Unichem Laboratories Ltd (UNICHEMLAB) reported revenue of ₹2,202 crore, net profit of ₹253 crore and earnings per share of ₹35.91. That compares with revenue of ₹2,111 crore and net profit of ₹138 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹575 crore and net profit ₹11 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,270 | 1,343 | 1,785 | 2,111 | 2,202 |
| Net profit (₹ cr) | 33 | -202 | -94 | 138 | 253 |
| EPS (₹) | 4.7 | -28.72 | -13.32 | 19.53 | 35.91 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.46% | 4.67% | 9.61% | 4.31% |
| Profit growth | - | 24.06% | - | 83.86% |
| Stock price CAGR | 7% | 12% | 16% | -6% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 70.22% of Unichem Laboratories Ltd (UNICHEMLAB) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.9% and domestic institutional investors (DII) hold 10.46%. Market capitalisation was ₹4,502 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Hdfc Small Cap Fund 7.75%, Dsp Healthcare Fund 1.56%, Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 1.04%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 70.22% | - | 0.9% | 10.46% | 29.78% |
| Mar 2026 | 70.22% | - | 1% | 10.63% | 29.78% |
| Dec 2025 | 70.22% | - | 0.99% | 10.74% | 29.78% |
| Sep 2025 | 70.22% | - | 1% | 10.75% | 29.78% |
| Jun 2025 | 70.22% | - | 0.98% | 10.92% | 29.78% |
| Mar 2025 | 70.22% | - | 0.98% | 11.32% | 29.78% |
| Dec 2024 | 70.22% | - | 1.06% | 11.63% | 29.78% |
| Sep 2024 | 70.22% | - | 0.94% | 11.67% | 29.78% |